BACKGROUND: Treatment of relapsed hematological malignancies after an allogeneic
peripheral blood stem cell transplant (SCT) is challenging. Donor lymphocyte infusion (DLI) …

Background Patients with hematologic malignancies in relapse after allogeneic bone
marrow transplantation can be treated by infusing leukocytes from the original stem cell …

Introduction: Allogeneic hematopoietic stem cell transplantation (SCT) is the treatment of
choice for many malignant hematological disorders. Following recent improvements in non …

Donor lymphocyte infusion (DLI) using unstimulated leukapheresis is one of the most
effective treatment strategies for patients with hematological malignancies; its graft-versus …

Aims: There is a perceived benefit associated with the administration of donor lymphocyte
infusion (DLI) in patients with lymphoid malignancies relapsing after allogeneic …

Donor lymphocyte infusions (DLIs) can induce complete and durable remissions in some
patients with hematologic malignancies who have relapsed after allogeneic transplantation …

Donor lymphocyte infusions for treatment of relapse after allogeneic bone marrow or stem
cell transplantation is being used with increasing frequency. Study of this form of adoptive …

To evaluate the safety and efficacy of donor lymphocyte infusion (DLI), we retrospectively
analyzed 414 recipients who received unrelated DLI (UDLI) for the treatment of relapsed …

OBJECTIVE: Donor lymphocyte infusions (DLI) can induce durable second remissions in
patients relapsed after allogeneic stem cell transplantation (SCT) for hematologic …

The graft-versus-malignancy (GVM) effect is the therapeutic cornerstone of allogeneic stem
cell transplantation (SCT). Lymphocytes of donor origin have been recognized as decisive …